ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.2314A>G (p.Thr772Ala)

dbSNP: rs1573574121
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001015143 SCV001175947 uncertain significance Hereditary cancer-predisposing syndrome 2021-06-30 criteria provided, single submitter clinical testing The p.T772A variant (also known as c.2314A>G), located in coding exon 14 of the MSH2 gene, results from an A to G substitution at nucleotide position 2314. The threonine at codon 772 is replaced by alanine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV001202641 SCV001373763 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2021-05-19 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site, but this prediction has not been confirmed by published transcriptional studies. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with MSH2-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with alanine at codon 772 of the MSH2 protein (p.Thr772Ala). The threonine residue is moderately conserved and there is a small physicochemical difference between threonine and alanine.
Sema4, Sema4 RCV001015143 SCV002534466 uncertain significance Hereditary cancer-predisposing syndrome 2021-08-11 criteria provided, single submitter curation
Color Diagnostics, LLC DBA Color Health RCV001015143 SCV004356736 uncertain significance Hereditary cancer-predisposing syndrome 2021-11-23 criteria provided, single submitter clinical testing This missense variant replaces threonine with alanine at codon 772 of the MSH2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.